We are live on
!
Find out more
SCM
Silverarc Capital Management Portfolio holdings
AUM
$849M
1-Year Est. Return
470.8%
This Fund
S&P 500
This Quarter
Est. Return
+33.87%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$324M
AUM Growth
+$55.8M
(+21%)
Cap. Flow
-$5.31M
Cap. Flow
% of AUM
-1.64%
Top 10 Holdings %
Top 10 Hldgs %
40.14%
Holding
88
New
16
Increased
28
Reduced
14
Closed
20
Top Buys
| 1 |
Nuvalent
NUVL
|
+$11.9M |
| 2 |
Sanofi
SNY
|
+$10.8M |
| 3 |
Medtronic
MDT
|
+$10.3M |
| 4 |
Rocket Pharmaceuticals
RCKT
|
+$8.45M |
| 5 |
Celldex Therapeutics
CLDX
|
+$7.27M |
Top Sells
| 1 |
IMGN
Immunogen Inc
IMGN
|
+$20.7M |
| 2 |
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
|
+$11.2M |
| 3 |
SLNO
Soleno Therapeutics
SLNO
|
+$8.43M |
| 4 |
Krystal Biotech
KRYS
|
+$8.3M |
| 5 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$7.41M |
Sector Composition
| 1 | Healthcare | 99.98% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
MRUS
1
DELISTED
Merus
MRUS
| $17.8M | 5.48% |
645,581
+145,581
| +29% | +$3.4M |
|
|
MRSN
2
DELISTED
Mersana Therapeutics
MRSN
| $14.9M | 4.59% |
256,805
+56,805
| +28% | +$2.29M |
|
|
MORF
3
DELISTED
Morphic Holding, Inc. Common Stock
MORF
| $14.4M | 4.45% |
500,042
-90,787
| -15% | -$2.16M |
|
|
4
Nuvalent
NUVL
$9.81B
| $14.2M | 4.38% |
+193,000
| New | +$11.9M |
|
|
PSTX
5
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
| $12.5M | 3.84% |
3,705,779
+137,794
| +4% | +$355K |
|
6
MacroGenics
MGNX
$275M
| $12.1M | 3.73% |
1,258,641
-5,517
| -0.4% | -$38.1K |
|
|
7
Rocket Pharmaceuticals
RCKT
$399M
| $11.5M | 3.54% |
+382,672
| New | +$8.45M |
|
|
8
Medtronic
MDT
$103B
| $11.1M | 3.43% |
+135,000
| New | +$10.3M |
|
|
9
Sanofi
SNY
$105B
| $10.9M | 3.37% |
+220,000
| New | +$10.8M |
|
10
Oric Pharmaceuticals
ORIC
$1.15B
| $10.8M | 3.32% |
1,170,000
+46,655
| +4% | +$337K |
|
|
11
Celldex Therapeutics
CLDX
$3.01B
| $9.8M | 3.02% |
+247,215
| New | +$7.27M |
|
12
Olema Pharmaceuticals
OLMA
$1.03B
| $8.05M | 2.48% |
573,830
+166,029
| +41% | +$2.23M |
|
13
Rhythm Pharmaceuticals
RYTM
$7.52B
| $8.01M | 2.47% |
174,248
-86,289
| -33% | -$2.72M |
|
14
UroGen Pharma
URGN
$1.94B
| $7.88M | 2.43% |
525,404
+16,521
| +3% | +$214K |
|
15
Xenon Pharmaceuticals
XENE
$6.55B
| $7.52M | 2.32% |
163,168
+109,172
| +202% | +$3.86M |
|
16
Veracyte
VCYT
$4.75B
| $6.81M | 2.1% |
247,723
+8,152
| +3% | +$197K |
|
17
Praxis Precision Medicines
PRAX
$8.88B
| $6.32M | 1.95% |
283,841
+9,313
| +3% | +$168K |
|
|
AKRO
18
DELISTED
Akero Therapeutics
AKRO
| $5.82M | 1.8% |
249,254
+217,918
| +695% | +$4.3M |
|
19
Pliant Therapeutics
PLRX
$69.4M
| $5.77M | 1.78% |
318,524
+68,115
| +27% | +$1.04M |
|
|
ITCI
20
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $5.73M | 1.77% |
80,000
-128,730
| -62% | -$7.41M |
|
21
Cogent Biosciences
COGT
$6.72B
| $5.68M | 1.75% |
966,748
+315,376
| +48% | +$2.42M |
|
|
ALPN
22
DELISTED
Alpine Immune Sciences Inc
ALPN
| $5.68M | 1.75% |
+297,789
| New | +$4.14M |
|
23
Gossamer Bio
GOSS
$79M
| $5.59M | 1.73% |
6,130,268
| – | – |
|
24
Intuitive Surgical
ISRG
$138B
| $5.33M | 1.64% |
+15,808
| New | +$4.71M |
|
25
TELA Bio
TELA
$35.2M
| $5.26M | 1.62% |
795,080
+304,609
| +62% | +$1.76M |
|
Similar funds
BOTOTLSJU
LA
EPIMS
CFP
USAA
OMC
AIA
EBSAM